ALK and neoplasm: ROS1 rearrangements, found in 1−2% of NSCLC patients, are identified as oncogenic drivers, creating a distinct molecular subgroup of NSCLCs since it is rare for ALK and ROS1 rearrangements to occur in the same tumor.